| Market Cap | 13.30M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -4.5M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -17.00% |
| Sales | 4.45M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -21.00% |
| Dividend | N/A | Price/Book | 0.55 | EPS next 5Y | - | 52W High Chg | -55.00% |
| Recommedations | - | Quick Ratio | 1.93 | Shares Outstanding | 274.80M | 52W Low Chg | 50.00% |
| Insider Own | 22.57% | ROA | -17.04% | Shares Float | 167.47M | Beta | 0.72 |
| Inst Own | 17.77% | ROE | -33.05% | Shares Shorted/Prior | -/- | Price | 0.05 |
| Gross Margin | 90.07% | Profit Margin | -101.14% | Avg. Volume | 2,466 | Target Price | - |
| Oper. Margin | -170.08% | Earnings Date | Nov 18 | Volume | 10,120 | Change | 0.00% |
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer, other solid tumors, other fibrotic disease, and scar reduction which is in clinical trial. It also develops AMP886, which is in preclinical trial for treating solid tumors. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.